找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Disease Recurrence After Liver Transplantation; Natural History, Tre Paul J. Thuluvath Book 2016 Springer Science+Business Media New York 2

[復(fù)制鏈接]
樓主: otitis-externa
21#
發(fā)表于 2025-3-25 04:28:42 | 只看該作者
Cholangiocarcinoma,modal therapies including neoadjuvant chemotherapy and/or radiation, and surgical exploration followed by LTX offer patient survival rates comparable to LTX done for other liver disease etiologies in a select group of patients. At this time, LTX for cholangiocarcinoma should be performed using stric
22#
發(fā)表于 2025-3-25 07:45:25 | 只看該作者
Recurrent Non-hepatic and De Novo Malignancies After Liver Transplantation,rson-years calculated by adding survival of each patient) are compared with epidemiological data for each cancer type. This method provides the precise incidence of cancer post-LTx compared to general population. Rates of malignancy increase in proportion to age at transplant and length of follow-up
23#
發(fā)表于 2025-3-25 13:18:16 | 只看該作者
24#
發(fā)表于 2025-3-25 17:31:15 | 只看該作者
25#
發(fā)表于 2025-3-25 22:13:09 | 只看該作者
Ivica Milevski,Ekaterina Ivanovaotentially reverses the consequences and complications of the initial abnormalities depending on the severity of the complications, reversibility, and time interval between the diagnosis of the problem and replacement of the liver.
26#
發(fā)表于 2025-3-26 00:09:16 | 只看該作者
27#
發(fā)表于 2025-3-26 04:47:32 | 只看該作者
28#
發(fā)表于 2025-3-26 11:05:50 | 只看該作者
vered.As there is a high incidence of disease recurrence after liver transplantation, this volume is designed around the need for a reference text dealing exclusively with this problem. The book places special emphasis on pre- and post-transplant predictors of recurrence, severity assessment, prophy
29#
發(fā)表于 2025-3-26 14:10:09 | 只看該作者
30#
發(fā)表于 2025-3-26 18:50:32 | 只看該作者
Ivica Milevski,Ekaterina Ivanovaion resulting in cardiovascular events—which is considered today the leading cause of death following liver transplantation in NASH recipients, surpassed only by sepsis. Patients with NASH cirrhosis should be carefully evaluated and selected for liver transplantation, and metabolic risk factors should be treated aggressively.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 17:29
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
日照市| 新龙县| 太白县| 平利县| 奈曼旗| 利辛县| 扎囊县| 涞水县| 抚顺市| 富源县| 广州市| 贵南县| 军事| 五莲县| 承德市| 天水市| 岳西县| 裕民县| 湖南省| 达尔| 南投县| 永州市| 青阳县| 阳原县| 神农架林区| 镇巴县| 陵川县| 准格尔旗| 富阳市| 辽中县| 东源县| 兰西县| 航空| 万荣县| 普陀区| 马边| 韩城市| 崇文区| 杂多县| 西华县| 琼中|